Kazia Therapeutics
KZIA
7 hedge funds and large institutions have $52.8K invested in Kazia Therapeutics in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
43% less capital invested
Capital invested by funds: $92K → $52.8K (-$39.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$12.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.45K |
| 3 |
BWFA
Baltimore-Washington Financial Advisors
Columbia,
Maryland
|
+$4.61K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$768 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$52K |
| 2 |
Morgan Stanley
New York
|
-$6.92K |
| 3 |
PP
Palladium Partners
Norfolk,
Virginia
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of America
Charlotte,
North Carolina
| $15K | – | – | – |
|
|
BRWA
2
B. Riley Wealth Advisors
Boca Raton,
Florida
| $11.8K | +$12.3K | +16 | New |
|
|
3
Morgan Stanley
New York
| $8K | -$6.92K | -9 | -43% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $8K | +$8.45K | +11 | New |
|
|
U
5
UBS
Zurich,
Switzerland
| $5K | +$768 | +1 | +17% |
|
|
BWFA
6
Baltimore-Washington Financial Advisors
Columbia,
Maryland
| $4K | +$4.61K | +6 | New |
|
7
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$52K | -63 | Closed |
|
|
PP
9
Palladium Partners
Norfolk,
Virginia
| – | -$1K | -1 | Closed |
|
KZIA Hedge Fund Activity: Q2 2014 in Review
7 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2014, worth a combined $52.8K — down 43% from $92K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KZIA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was B. Riley Wealth Advisors, opening a new position worth an estimated $12.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $52K sold.
- 7 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2014, up from 6 in Q1 2014.
- Funds reported $52.8K of Kazia Therapeutics stock for Q2 2014, down 43% quarter-over-quarter.
- 3 funds opened new Kazia Therapeutics positions in Q2 2014 and 2 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q2 2014 was B. Riley Wealth Advisors, an estimated $12.3K added.
- The largest Kazia Therapeutics seller in Q2 2014 was Citadel Advisors, an estimated $52K sold.
Based on aggregated 13F filings for Q2 2014.